Abiopharma

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

New Form EFFECT - Blueprint Medicines Corp Filed: 2025-07-24 AccNo: 9999999995-25-002337 Size: 1 KB

New Form EFFECT - electroCore, Inc. Filed: 2025-07-24 AccNo: 9999999995-25-002339 Size: 1 KB

New Form EFFECT - OneMedNet Corp Filed: 2025-07-24 AccNo: 9999999995-25-002338 Size: 1 KB

New Form EFFECT - Vireo Growth Inc. Filed: 2025-07-24 AccNo: 9999999995-25-002353 Size: 1 KB

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

FDA approve FLUCYTOSINE

FDA approve MICAFUNGIN SODIUM

FDA approve CARVEDILOL

FDA approve TOPIRAMATE

FDA approve DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

FDA approve VORICONAZOLE

FDA approve AMPICILLIN SODIUM; SULBACTAM SODIUM

Ceasing to be a substantial holder